Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study
Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
Sammy Elmariah1,2, Cian McCarthy3, Nasrien Ibrahim3
1Cardiology Division, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Insights
Researchers developed a new blood test using multiple biomarkers to help diagnose severe aortic valve stenosis (AS). This novel approach aids in identifying patients with this challenging cardiovascular condition.
Area of Science:
- Cardiovascular Medicine
- Biomarker Discovery
- Diagnostic Development
Background:
- Severe aortic valve stenosis (AS) presents diagnostic challenges due to its insidious nature.
- Early and accurate diagnosis is crucial for effective patient management.
Purpose of the Study:
- To develop a circulating biomarker panel for identifying patients with severe AS.
- To create a diagnostic model integrating clinical and biomarker data.
Main Methods:
- A panel of 109 proteins was measured in blood samples from 1244 participants undergoing angiography.
- Statistical learning identified key biomarkers (N-terminal pro-B-type natriuretic peptide, von Willebrand factor, fetuin-A) and clinical parameters (age).
- A diagnostic model was developed and validated using Monte Carlo cross-validation.
Main Results:
- The final model, including age, N-terminal pro-B-type natriuretic peptide, von Willebrand factor, and fetuin-A, showed good discrimination for severe AS (AUC=0.74).
- A diagnostic score was generated, correlating with AS severity and inversely with aortic valve area (AVA).
- The model achieved 76% sensitivity and 65% specificity at the optimal cut-off.
Conclusions:
- A novel, multi-biomarker approach for the diagnostic evaluation of severe AS has been described.
- This panel offers a promising tool for improving the identification of patients with severe AS.
Objective:
Severe aortic valve stenosis (AS) develops via insidious processes and can be challenging to correctly diagnose. We sought to develop a circulating biomarker panel to identify patients with severe AS.
Methods:
We enrolled study participants undergoing coronary or peripheral angiography for a variety of cardiovascular diseases at a single academic medical centre. A panel of 109 proteins were measured in blood obtained at the time of the procedure. Statistical learning methods were used to identify biomarkers and clinical parameters that associate with severe AS. A diagnostic model incorporating clinical and biomarker results was developed and evaluated using Monte Carlo cross-validation.
Results:
Of 1244 subjects (age 66.4±11.5 years, 28.7% female), 80 (6.4%) had severe AS (defined as aortic valve area (AVA) <1.0 cm2). A final model included age, N-terminal pro-B-type natriuretic peptide, von Willebrand factor and fetuin-A. The model had good discrimination for severe AS (OR=5.9, 95% CI 3.5 to 10.1, p<0.001) with an area under the curve of 0.76 insample and 0.74 with cross-validation. A diagnostic score was generated. Higher prevalence of severe AS was noted in those with higher scores, such that 1.6% of those with a score of 1 had severe AS compared with 15.3% with a score of 5 (p<0.001), and score values were inversely correlated with AVA (r=-0.35; p<0.001). At optimal model cut-off, we found 76% sensitivity, 65% specificity, 13% positive predictive value and 98% negative predictive value.
Conclusions:
We describe a novel, multiple biomarker approach for diagnostic evaluation of severe AS.
Trial Registration Number:
NCT00842868.
Related Concept Videos
Wood Panel Products
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Mitral Stenosis I: Introduction
Multiple Allele Traits
Mitral Stenosis III: Medical Management

